Passage Bio’s Growth Potential Highlighted by Clinical Progress and Regulatory Alignment

Yun Zhong, an analyst from Wedbush, reiterated the Buy rating on Passage Bio. The associated price target was lowered to $32.00.

Yun Zhong has given his Buy rating due to a combination of factors that highlight Passage Bio’s potential for growth and success. The company is making significant progress in its clinical trials, specifically with the PBFT02 program, which targets frontotemporal dementia (FTD). The ongoing patient enrollment and anticipated clinical updates in the first half of 2026 are expected to act as strong catalysts for the stock.
Additionally, Passage Bio’s alignment with the FDA on manufacturing processes and the potential for a single-arm registrational study demonstrate the company’s proactive approach to regulatory hurdles. The promising biomarker data, including sustained CSF PRGN expression and reduced NfL levels, further support the potential efficacy of PBFT02. These factors, combined with a solid cash runway into the first quarter of 2027, underpin Yun Zhong’s optimistic outlook and the reiterated Outperform rating for Passage Bio.